MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT) today announced its schedule of major activities for the EuroPCR meeting, which begins May 22 at the Centre Convencións Internaciónal Barcelona (CCIB) in Barcelona, Spain. Highlighting the activities are two presentations at the late-breaking clinical trials session on the first day. During that session, Medtronic will present key nine-month results for Endeavor Resolute, its next-generation drug-eluting stent, as well as long-term data from the ENDEAVOR I and ENDEAVOR II clinical trials on the Endeavor™ drug-eluting stent.
